Skip to main content

Advertisement

SpringerLink
Log in

CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

To understand the mechanism of transcriptional down-regulation of BRCA1 by promoter methylation, we screened 51 breast cancer cell lines and identified HCC38 as another BRCA1 promoter-methylated cell line in addition to UACC3199. There was low expression of BRCA1 mRNA and BRCA1 protein in both cell lines as measured by quantitative RT-PCR and western blot analysis. After transient treatment with 5-aza-2′-deoxycytidine (5-aza-CdR) and trichostatin A (TSA), re-expression of BRCA1 mRNA and BRCA1 protein was detected in UACC3199 cells, but not in HCC38 cells. Another demethylating agent, zebularine, did not induce BRCA1 re-expression in either cell line. To test the hypothesis that methylation of CpG sites may affect accessibility of the BRCA1 promoter to transcription factors and consequently cause down-regulation of BRCA1, we analyzed the binding of four transcription factors (CTCF, Sp1, E2F1 and E2F6) to the BRCA1 promoter using chromatin immunoprecipitation assay (ChIP) and quantitative PCR. CTCF and E2F1 were enriched at the unmethylated BRCA1 promoter in MCF-7 cells. In contrast, these two transcription factors were not enriched at the methylated BRCA1 promoter in UACC3199 and HCC38 cells. Following demethylating drug treatment, E2F1 was enriched at the BRCA1 promoter in the demethylated UACC3199 cells. This indicates that reduced accessibility of transcription factors to the methylated promoter is one of the mechanisms for down-regulation of BRCA1 in heavily methylated cancer cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y et al (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266(5182):120–122. doi:10.1126/science.7939630

    Article  CAS  PubMed  Google Scholar 

  2. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC (1998) Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279(12):915–921. doi:10.1001/jama.279.12.915

    Article  CAS  PubMed  Google Scholar 

  3. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA et al (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92(7):564–569. doi:10.1093/jnci/92.7.564

    Article  CAS  PubMed  Google Scholar 

  4. Mueller CR, Roskelley CD (2003) Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res 5(1):45–52. doi:10.1186/bcr557

    Article  CAS  PubMed  Google Scholar 

  5. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415–428

    CAS  PubMed  Google Scholar 

  6. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349(21):2042–2054. doi:10.1056/NEJMra023075

    Article  CAS  PubMed  Google Scholar 

  7. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128(4):683–692. doi:10.1016/j.cell.2007.01.029

    Article  CAS  PubMed  Google Scholar 

  8. Catteau A, Morris JR (2002) BRCA1 methylation: a significant role in tumour development? Semin Cancer Biol 12(5):359–371. doi:10.1016/S1044-579X(02)00056-1

    Article  CAS  PubMed  Google Scholar 

  9. Rice JC, Massey-Brown KS, Futscher BW (1998) Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 17(14):1807–1812. doi:10.1038/sj.onc.1202086

    Article  CAS  PubMed  Google Scholar 

  10. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D et al (1999) Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21(2):236–240. doi:10.1038/6029

    Article  CAS  PubMed  Google Scholar 

  11. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW (2000) Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21(9):1761–1765. doi:10.1093/carcin/21.9.1761

    Article  CAS  PubMed  Google Scholar 

  12. Okochi E, Miyamoto K, Wakazono K, Shima H, Sugimura T, Ushijima T (2002) Reduced Brca1 protein expression in 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine-induced rat mammary carcinomas. Mol Carcinog 34(4):211–218. doi:10.1002/mc.10065

    Article  CAS  PubMed  Google Scholar 

  13. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL (2005) BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 91(2):179–186. doi:10.1007/s10549-004-7603-8

    Article  CAS  PubMed  Google Scholar 

  14. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S et al (2005) BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 65(23):10692–10699. doi:10.1158/0008-5472.CAN-05-1277

    Article  CAS  PubMed  Google Scholar 

  15. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5(1):37–50. doi:10.1038/nrd1930

    Article  CAS  PubMed  Google Scholar 

  16. Lin KT, Momparler RL, Rivard GE (1981) High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine. J Pharm Sci 70(11):1228–1232. doi:10.1002/jps.2600701112

    Article  CAS  PubMed  Google Scholar 

  17. Juttermann R, Li E, Jaenisch R (1994) Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 91(25):11797–11801. doi:10.1073/pnas.91.25.11797

    Article  CAS  PubMed  Google Scholar 

  18. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F (2006) Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66(5):2794–2800. doi:10.1158/0008-5472.CAN-05-2821

    Article  CAS  PubMed  Google Scholar 

  19. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU (2003) Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95(5):399–409

    Article  CAS  PubMed  Google Scholar 

  20. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez VE, Jones PA (2004) Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24(3):1270–1278. doi:10.1128/MCB.24.3.1270-1278.2004

    Article  CAS  PubMed  Google Scholar 

  21. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, Marquez VE, Greer S, Orntoft TF, Thykjaer T et al (2004) Preferential response of cancer cells to zebularine. Cancer Cell 6(2):151–158. doi:10.1016/j.ccr.2004.06.023

    Article  CAS  PubMed  Google Scholar 

  22. Butcher DT, Mancini-DiNardo DN, Archer TK, Rodenhiser DI (2004) DNA binding sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter. Int J Cancer 111(5):669–678. doi:10.1002/ijc.20324

    Article  CAS  PubMed  Google Scholar 

  23. Wang A, Schneider-Broussard R, Kumar AP, MacLeod MC, Johnson DG (2000) Regulation of BRCA1 expression by the Rb-E2F pathway. J Biol Chem 275(6):4532–4536. doi:10.1074/jbc.275.6.4532

    Article  CAS  PubMed  Google Scholar 

  24. Oberley MJ, Inman DR, Farnham PJ (2003) E2F6 negatively regulates BRCA1 in human cancer cells without methylation of histone H3 on lysine 9. J Biol Chem 278(43):42466–42476. doi:10.1074/jbc.M307733200

    Article  CAS  PubMed  Google Scholar 

  25. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, Glazer PM (2005) Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 65(24):11597–11604. doi:10.1158/0008-5472.CAN-05-2119

    Article  CAS  PubMed  Google Scholar 

  26. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93(18):9821–9826. doi:10.1073/pnas.93.18.9821

    Article  CAS  PubMed  Google Scholar 

  27. Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, Grushko TA, Olopade OI (2008) Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat 111(1):113–120. doi:10.1007/s10549-007-9766-6

    Article  CAS  PubMed  Google Scholar 

  28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408. doi:10.1006/meth.2001.1262

    Article  CAS  PubMed  Google Scholar 

  29. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B (2001) Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 15(16):2069–2082. doi:10.1101/gad.906601

    Article  CAS  PubMed  Google Scholar 

  30. Bell AC, West AG, Felsenfeld G (1999) The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98(3):387–396. doi:10.1016/S0092-8674(00)81967-4

    Article  CAS  PubMed  Google Scholar 

  31. Filippova GN, Thienes CP, Penn BH, Cho DH, Hu YJ, Moore JM, Klesert TR, Lobanenkov VV, Tapscott SJ (2001) CTCF-binding sites flank CTG/CAG repeats and form a methylation-sensitive insulator at the DM1 locus. Nat Genet 28(4):335–343. doi:10.1038/ng570

    Article  CAS  PubMed  Google Scholar 

  32. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM (2000) CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405(6785):486–489. doi:10.1038/35013106

    Article  CAS  PubMed  Google Scholar 

  33. Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y, de La Chapelle A (2001) Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA 98(2):591–596. doi:10.1073/pnas.011528698

    Article  CAS  PubMed  Google Scholar 

  34. Ishihara K, Oshimura M, Nakao M (2006) CTCF-dependent chromatin insulator is linked to epigenetic remodeling. Mol Cell 23(5):733–742. doi:10.1016/j.molcel.2006.08.008

    Article  CAS  PubMed  Google Scholar 

  35. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18(5):956–962

    CAS  PubMed  Google Scholar 

  36. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J et al (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5):1635–1640. doi:10.1182/blood-2003-03-0687

    Article  CAS  PubMed  Google Scholar 

  37. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23(17):3948–3956. doi:10.1200/JCO.2005.11.981

    Article  CAS  PubMed  Google Scholar 

  38. Yoo CB, Cheng JC, Jones PA (2004) Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans 32(Pt 6):910–912. doi:10.1042/BST0320910

    CAS  PubMed  Google Scholar 

  39. Chuang JC, Yoo CB, Kwan JM, Li TW, Liang G, Yang AS, Jones PA (2005) Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol Cancer Ther 4(10):1515–1520. doi:10.1158/1535-7163.MCT-05-0172

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Grant support: National Institute of Environmental Health Sciences grant P50 ES012382, NIH-National Cancer Institute Cancer Center Support grant 3P30 CA 23074, the Breast Cancer Research Foundation, the National Women’s Cancer Research Alliance, and the Falk Medical Research Trust (O.I. Olopade). We thank Olopade lab members for helpful discussion. We also thank Michelle Porcellino and Lisa Sveen for critical reading of the manuscript.

Author information

Authors and Affiliations

  1. Department of Medicine, Center for Clinical Cancer Genetics, University of Chicago, Chicago, IL, 60637-1463, USA

    Jinhua Xu, Yinghua Chen, Chika Nwachukwu, Cindy Collins, Janelle Rowell & Olufunmilayo I. Olopade

  2. Department of Health Studies, University of Chicago, Chicago, IL, 60637-1463, USA

    Dezheng Huo

  3. Department of Medicine, University of California at Los Angeles, Los Angeles, CA, 90095, USA

    Dennis J. Slamon

  4. Department of Human Genetics, University of Chicago, Chicago, IL, 60637-1463, USA

    Olufunmilayo I. Olopade

Authors
  1. Jinhua Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dezheng Huo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yinghua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chika Nwachukwu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cindy Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Janelle Rowell
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dennis J. Slamon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Olufunmilayo I. Olopade
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olufunmilayo I. Olopade.

Electronic supplementary material

Below is the link to the electronic supplementary material.

(DOCX 10 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, J., Huo, D., Chen, Y. et al. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors. Breast Cancer Res Treat 120, 593–601 (2010). https://doi.org/10.1007/s10549-009-0422-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0422-1

Keywords

Search

Navigation